ID: h-6b814d561d
Hypothesis
The most realistic translational use of physiological SCFAs is as an adjunct to GLP-1 receptor agonism or NLRP3 inhibition rather than monotherapy
Physiological SCFA elevation may generate a weak, context-dependent signal that is insufficient alone but could become beneficial when paired with a clinically stronger pathway such as GLP-1 receptor agonism or with suppression of inflam.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Physiological SCFA elevation may generate a weak, context-dependent signal that is insufficient alone but could become beneficial when paired with a clinically stronger pathway such as GLP-1 receptor agonism or with suppression of inflammasome activation. This is a viable research strategy, although a positive combination result would not by itself prove that SCFAs directly enhance alpha-synuclein clearance.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Target Gene: GLP1R/NLRP3"]
B["Molecular Mechanism<br/>Pathway Activation"]
C["Cellular Phenotype<br/>Neuronal / Glial Response"]
D["Network Effect<br/>Circuit-Level Consequence"]
E["Disease Relevance<br/>Neurodegeneration Link"]
A --> B --> C --> D --> E
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style E fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix3 supports2 contradicts
Supports
SCFAs show beneficial associations in some butyrate and GLP-1-linked PD studies, suggesting an upstream modulatory role.
Supports
SCFA-associated worsening in synucleinopathy and inflammasome-linked models supports the idea that co-targeting inflammatory liabilities may be necessary.
Supports
Recent work implicating GPR43-NLRP3 signaling provides a mechanistic basis for combining physiologic SCFA elevation with inflammasome blockade.
Contradicts
Combination benefit could be driven entirely by the partner therapy, leaving the SCFA component neutral or harmful.
Contradicts
This hypothesis currently reconciles contradictory results rather than being directly demonstrated.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — GLP1R
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for GLP1R/NLRP3 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for GLP1R.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
—
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.4%
Volatility
Low
0.0029
Events (7d)
2
Price History
▼9.5%💾 Resource Usage
LLM Tokens
19,114
$0.0573
Total Cost
$0.0573
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 12 weeks) is co-administered with a GLP-1R agonist (liraglutide 30 nmol/kg t | ≥20% reduction in striatal pSer129 alpha-synuclein pathology and ≥15% improvement in rotarod latency to fall compared to GLP-1R agonist monotherapy | — no observation — | pending | 0.65 |
| IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 8 weeks) is co-administered with an NLRP3 inhibitor (MCC950 10 mg/kg daily, | ≥25% reduction in cortical caspase-1 fluorometric activity and ≥20% improvement in Y-maze spontaneous alternation percentage compared to MCC950 monotherapy | — no observation — | pending | 0.58 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 12 weeks) is co-administered with a GLP-1R agonist (liraglutide 30 nmol/kg twice daily, intraperitoneal) to alpha-synuclein pre-formed fibril (PFF) mice, THEN combined treatmen
Predicted outcome: ≥20% reduction in striatal pSer129 alpha-synuclein pathology and ≥15% improvement in rotarod latency to fall compared to GLP-1R agonist monotherapy
Falsification: If combined SCFA+GLP-1R treatment produces no statistically significant difference (p>0.05) in alpha-synuclein aggregation or motor outcomes compared to GLP-1R agonist alone, the adjunct hypothesis fo
pendingconf 58%
IF physiological-dose SCFA mixture (sodium propionate 20mM, sodium butyrate 10mM, sodium acetate 30mM in drinking water for 8 weeks) is co-administered with an NLRP3 inhibitor (MCC950 10 mg/kg daily, intraperitoneal) to 6-month-old APP/PS1 mice, THEN combined treatment will produce significantly gre
Predicted outcome: ≥25% reduction in cortical caspase-1 fluorometric activity and ≥20% improvement in Y-maze spontaneous alternation percentage compared to MCC950 monoth
Falsification: If combined SCFA+MCC950 treatment produces no statistically significant difference (p>0.05) in inflammasome markers or cognitive outcomes compared to MCC950 inhibitor alone, the adjunct hypothesis for
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.